
# The NgenIRS partnership – saving lives through novel IRS delivery and multiple partner collaborations




## Unitaid's strategy and positioning


<u>Unitaid's mission:</u> maximize the effectiveness of the global health response by catalyzing equitable access to better health products



## Overview of Unitaid's current malaria portfolio




### Rationale for intervention



# Market context of IRS (pre- NgenIRS) 1/2

- A long-lasting non-pyrethroid insecticide (3<sup>rd</sup> generation IRS; or "3GIRS") available for IRS
- Early data highly effective in reducing malaria transmission
- Only represented 3.8% of total IRS coverage in 2013

### Impact of 3GIRS in Ghana



### Switch to 3GIRS

- >55% decrease in RDT positives & childhood parasitaemia
- 50% decrease in fever
- 30% decrease in anaemia

Source: Abt & PMI, In preparation for publication



# Market context of IRS (pre- NgenIRS) 2/2

- Affordability a key barrier to adoption of 3GIRS \$23.50/unit vs. \$2-4 for pyrethroids
- IRS coverage decreased due to higher cost of non-pyrethroids- PMI estimated a 24% decrease in 2014
- Market evolution without intervention best case is slow growth, worst case is a
  decline
- Small, potentially shrinking market limits incentives for R&D
- Another key barrier to resistance management was availability
  - WHO recommends rotating insecticides used in IRS, but not enough products available